RLAYRelay Therapeutics, Inc.

$19.45

$3.2252 weeks$20.77

Price

$19.45+457%1Y

1M+1.9%1Y+457%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value95

Quality30

Momentum95

Growth12

Strongest Value, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Our Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Precision medicine emerged as an approach for disease treatment as the understanding of the link between genetic alterations, protein dysfunction and diseases evolved.

In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$3.46B

1Y Return+457%

5Y Return-41%

Relay Therapeutics, Inc. (RLAY) reported revenue of $350K in Q2 2026 (quarter ended June 30, 2026), down 48% from the same quarter a year earlier. That came with net loss of $84M. For the full year FY2025, revenue was $15M (+53% year on year) and net income −$276M.

Raw charts

8 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #42 of 145 by Smart Score

Compare peers

DNLI-0.36%

Denali Therapeutics Inc.

RCUS+5.0%

Arcus Biosciences, Inc.

ACAD+1.5%

ACADIA Pharmaceuticals Inc.

NAMS-2.8%

NewAmsterdam Pharma Company N.V.

CRNX-3.3%

Crinetics Pharmaceuticals, Inc.

TLX-0.37%

Telix Pharmaceuticals Limited